Your browser doesn't support javascript.
loading
Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository.
Gkrouzman, Elena; Sevim, Ecem; Finik, Jackie; Andrade, Danieli; Pengo, Vittorio; Sciascia, Savino; Tektonidou, Maria G; Ugarte, Amaia; Chighizola, Cecilia B; Belmont, H Michael; Lopez-Pedrera, Chary; Ji, Lanlan; Fortin, Paul; Efthymiou, Maria; de Jesus, Guilherme Ramires; Branch, D Ware; Nalli, Cecilia; Petri, Michelle; Rodriguez, Esther; Cervera, Ricard; Knight, Jason S; Atsumi, Tatsuya; Willis, Rohan; Bertolaccini, Maria Laura; Cohen, Hannah; Rand, Jacob; Erkan, Doruk.
Afiliación
  • Gkrouzman E; E. Gkrouzman, MD, MS, Hospital for Special Surgery, New York, New York, USA; egkrouzman@gmail.com.
  • Sevim E; E. Sevim, MD, Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, New York, USA.
  • Finik J; J. Finik, MPH, Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Andrade D; D. Andrade, MD, PhD, University of São Paulo, São Paulo, Brazil.
  • Pengo V; V. Pengo, MD, University Hospital Padova, Padova, Italy.
  • Sciascia S; S. Sciascia, MD, PhD, Center of Research of Immunopathology and Rare Diseases, University of Turin, Turin, Italy.
  • Tektonidou MG; M.G. Tektonidou, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece.
  • Ugarte A; A. Ugarte, MD, Hospital Universitario Cruces, Barakaldo, País Vasco, Spain.
  • Chighizola CB; C.B. Chighizola, MD, PhD, Clinical Immunology & Rheumatology Unit, IRCCS Istituto Auxologico Italiano, Milan, Italy.
  • Belmont HM; H.M. Belmont, MD, Hospital for Joint Diseases, New York University, New York, New York, USA.
  • Lopez-Pedrera C; C. Lopez-Pedrera, PhD, Rheumatology Service, IMIBIC/Reina Sofia Hospital, University of Cordoba, Cordoba, Spain.
  • Ji L; L. Ji, MD, Rheumatology and Immunology Department, Peking University First Hospital, Beijing, China.
  • Fortin P; P. Fortin, MD, CHU de Québec-Université Laval, Québec City, Québec, Canada.
  • Efthymiou M; M. Efthymiou, PhD, H. Cohen, MD, Haemostasis Research Unit, Department of Haematology, University College London, London, UK.
  • de Jesus GR; G. Ramires de Jesus, MD, MSc, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Branch DW; D.W. Branch, MD, University of Utah and Intermountain Healthcare, Salt Lake City, Utah, USA.
  • Nalli C; C. Nalli, MD, Rheumatology and Immunology Unit, ASST Spedali Civili of Brescia, Brescia, Italy.
  • Petri M; M. Petri, MD, MPH, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Rodriguez E; E. Rodriguez, MD, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Cervera R; R. Cervera, MD, PhD, FRCP, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain.
  • Knight JS; J.S. Knight, MD, PhD, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA.
  • Atsumi T; T. Atsumi, MD, PhD, Hokkaido University Hospital, Sapporo, Japan.
  • Willis R; R. Willis, MD, Antiphospholipid Standardization Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
  • Bertolaccini ML; M.L. Bertolaccini, PhD, Academic Department of Vascular Surgery, King's College London British Heart Foundation Centre of Excellence, School of Cardiovascular Medicine & Sciences, London, UK.
  • Cohen H; M. Efthymiou, PhD, H. Cohen, MD, Haemostasis Research Unit, Department of Haematology, University College London, London, UK.
  • Rand J; J. Rand, MD, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA.
  • Erkan D; D. Erkan, MD, MPH, Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, New York, USA.
J Rheumatol ; 48(4): 541-547, 2021 04.
Article en En | MEDLINE | ID: mdl-33259328
OBJECTIVE: The APS ACTION Registry studies long-term outcomes in persistently antiphospholipid antibody (aPL)-positive patients. Our primary objective was to determine whether clinically meaningful aPL profiles at baseline remain stable over time. Our secondary objectives were to determine (1) whether baseline characteristics differ between patients with stable and unstable aPL profiles, and (2) predictors of unstable aPL profiles over time. METHODS: A clinically meaningful aPL profile was defined as positive lupus anticoagulant (LAC) test and/or anticardiolipin (aCL)/anti-ß2 glycoprotein-I (anti-ß2-GPI) IgG/M ≥ 40 U. Stable aPL profile was defined as a clinically meaningful aPL profile in at least two-thirds of follow-up measurements. Generalized linear mixed models with logit link were used for primary objective analysis. RESULTS: Of 472 patients with clinically meaningful aPL profile at baseline (median follow-up 5.1 yrs), 366/472 (78%) patients had stable aPL profiles over time, 54 (11%) unstable, and 52 (11%) inconclusive. Time did not significantly affect odds of maintaining a clinically meaningful aPL profile at follow-up in univariate (P = 0.906) and multivariable analysis (P = 0.790). Baseline triple aPL positivity decreased (OR 0.25, 95% CI 0.10-0.64, P = 0.004) and isolated LAC test positivity increased (OR 3.3, 95% CI 1.53-7.13, P = 0.002) the odds of an unstable aPL profile over time. CONCLUSION: Approximately 80% of our international cohort patients with clinically meaningful aPL profiles at baseline remain stable at a median follow-up of 5 years; triple aPL-positivity increase the odds of a stable aPL profile. These results will guide future validation studies of stored blood samples through APS ACTION Core Laboratories.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndrome Antifosfolípido / Anticuerpos Antifosfolípidos Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Rheumatol Año: 2021 Tipo del documento: Article Pais de publicación: Canadá
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndrome Antifosfolípido / Anticuerpos Antifosfolípidos Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Rheumatol Año: 2021 Tipo del documento: Article Pais de publicación: Canadá